Systemic Therapy Approaches for Advanced Prostate Cancer
As part of the 2024 Prostate Cancer Patient Conference, Dr. Eric Small discusses systemic therapy treatment in advanced prostate cancer, including AR-targeted therapy. The presentation includes definitions of disease states, categories of treatment types, and standards in treatment selection.
Recorded on 03/09/2024. [Show ID: 39768]
Donate to UCTV to support informative & inspiring programming:
www.uctv.tv/donate
Please Note: Knowledge about health and medicine is constantly evolving. This information may become out of date.
More videos from: Prostate Cancer Patient Conference
(www.uctv.tv/prostate-cancer-c...)
Explore More Health & Medicine on UCTV
(www.uctv.tv/health)
UCTV features the latest in health and medicine from University of California medical schools. Find the information you need on cancer, transplantation, obesity, disease and much more.
UCTV is the broadcast and online media platform of the University of California, featuring programming from its ten campuses, three national labs and affiliated research institutions. UCTV explores a broad spectrum of subjects for a general audience, including science, health and medicine, public affairs, humanities, arts and music, business, education, and agriculture. Launched in January 2000, UCTV embraces the core missions of the University of California -- teaching, research, and public service - by providing quality, in-depth television far beyond the campus borders to inquisitive viewers around the world.
(www.uctv.tv)
Пікірлер: 5
Fabulous presentation. Where does Darolutamide fit into the picture?
@warrens.6229
8 күн бұрын
I have the same question. In January 2023 I was confirmed with Stage 4 with multiple bone lesions and an external tumor adjacent to the prostate and bladder. I was on Orgovyx (from the urologist) for one month before the oncologist switched me to Lupron and darolutamide) and the 6-cycle docetaxel regimen. According to this presentation, that was not justified although according to the local oncologist and Smilow Center at Yale New-Haven and MSKCC that is the treatment plan they all would use. BTW: because I had a family history and BPH, I was tested annually and my first reading over 4 was in August 2022 and it went 34 before I started with Orgovyx and the rest of the treatment plan. By May 30, my PSA was undetectable as it is today. I'm hoping the FDA approves Lutetium soon and that it would be effective for me. FWIW, my alkaline phosphatase went from 2844 to 100 in this time frame. It is holding steady in the 80's now.
At minute 11:53, Dr. Small is discussing treatment intensification using abiraterone (AA). In the K-M curve at minute 11:53, would somebody explain to me how the median survival of 53 months for ADT+AA was derived? The median is supposed to be the time point at which 50% of the population continues to survive. Based on the figures below the abcissa, that occurs at roughly 43 months. Same for the ADT only arm - the median should be roughly 31 months. What am I not understanding?
>>Undetectable levels of Prostate Specific Antigen (PSA) have been reported from the first patient with metastatic castrate-resistant prostate cancer (mCRPC) to ever receive two cycles of Clarity’s 67Cu-SAR-bisPSMA at the 8GBq dose level. PSA is a marker of tumour burden, clinical response to treatment and an indicator of the recurrence of disease for prostate cancer.